A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
- Autoimmune Disorder
- Inflammatory Bowel Disease (IBD)
- Ulcerative Colitis
Not yet recruiting
NCT06693908 GA45735
Trial Summary
This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).
A Phase Ic Open-label Study to Evaluate the Pharmacodynamic Effects, Pharmacokinetics, and Safety of Vixarelimab in Patients With Moderate to Severe Active Ulcerative Colitis
Eligibility Criteria
- Diagnosis of UC established at least 3 months
- Moderately to severely active UC
- Participants must meet criteria for either advanced therapy failure or conventional therapy failure
- Diagnosis of Crohn's disease or indeterminate colitis
- Suspicion of ischemic colitis, radiation colitis, microscopic colitis or infectious colitis
- Prior colectomy
- Prior treatment with systemic janus kinase (JAK) inhibitors
For the latest version of this information please go to www.forpatients.roche.com